Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection

A Atrasheuskaya, P Petzelbauer… - FEMS Immunology & …, 2003 - academic.oup.com
A Atrasheuskaya, P Petzelbauer, TM Fredeking, G Ignatyev
FEMS Immunology & Medical Microbiology, 2003academic.oup.com
Here we describe a lethal mouse model infected with dengue virus type 2 with several
similarities to human DEN-2 infection. Clinically animals demonstrated anemia,
thrombocytopenia, pre-terminal paralysis and shock. The most impressive changes were
seen with tumor necrosis factor (TNF)-α, which abruptly and steeply increased 24 h before
the exitus (mean at day 6). Serum levels of IL-1β, IL-6, IL-10, IL-1 receptor antagonist and
soluble TNF receptor I continuously increased during the time of infection. A 100% mortality …
Abstract
Here we describe a lethal mouse model infected with dengue virus type 2 with several similarities to human DEN-2 infection. Clinically animals demonstrated anemia, thrombocytopenia, pre-terminal paralysis and shock. The most impressive changes were seen with tumor necrosis factor (TNF)-α, which abruptly and steeply increased 24 h before the exitus (mean at day 6). Serum levels of IL-1β, IL-6, IL-10, IL-1 receptor antagonist and soluble TNF receptor I continuously increased during the time of infection. A 100% mortality rate was noted in that group of animals. Treating animals with anti-TNF-α serum reduced mortality rate down to 40% (P<;0.05). Our model supports the view that activation of innate immune response is at least partially responsible for mortality in DEN-2 infection, and in line with this concept, anti-TNF treatment significantly reduces mortality rates.
Oxford University Press